Paclitaxel liposomal - Aphios

Drug Profile

Paclitaxel liposomal - Aphios

Alternative Names: Liposome encapsulated paclitaxel - Aphios; Phospholipid nanosomes; Taxosomes

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aphios Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 18 Jan 2011 Aphios' paclitaxel liposomal is available for licensing as of 18 Jan 2011.
  • 22 Jun 2009 Paclitaxel liposomal is still in preclinical trials for Breast and ovarian cancers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top